Sanofi, GlaxoSmithKline report positive trial results of COVID-19 vaccine
Persons who were previously infected by the coronavirus produced high levels after a single injection, giving the companies hope that their vaccine could serve as an effective booster. The drugmakers plan to enroll more than 35,000 adults in multiple countries to test the shots against the original strain and the aggressive South Africa variant. Several COVID-19 vaccines are circulating now, though scientists say it is good to employ multiple options to bolster supply and have a range of vaccine platforms capable of fighting the wily virus. Sanofi’s recombinant technology inserts genetic in...